TJThomas P. Johnston

Thomas P. Johnston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas P. Johnston has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Effects of Pretreatment with Atorvastatin, Fenofibrate, or Both Drugs in a Mouse Model of Acute Lipemia Induced by the General Lipase Inhibitor Poloxamer 407

    by T. A. Korolenko, T. P. Johnston, N. V. Tamkovich, V. A. Vavilin, N. P. Bgatova, I. D. Ivanov, G. S. Russkikh, E. V. Koldysheva, E. C. Korolenko, V. I. Kapustina, et al.

    Dyslipidemia is a well-known risk factor for the development of cardiovascular diseases and atherosclerosis. The effects of combined pretreatment with atorvastatin and fenofibrate (Tricor) were studied in a mouse model of acute lipemia induced by a general lipase inhibitor, poloxamer 407 (P-407, 250 mg/kg). This lipemia is characterized by significantly increased serum levels of triglycerides (TG), low-density lipoprotein (LDL) cholesterol, together with decreased concentration of high-density lipoprotein (HDL) cholesterol. Atorvastatin pretreatment had a hypolipidemic effect, decreasing concentrations of LDL cholesterol and increasing HDL cholesterol. Pretreatment of mice with fenofibrate decreased TG level, increasing HDL cholesterol. Combined pretreatment with atorvastatin and fenofibrate decreased TG and total cholesterol. Elevation of the serum cystatin C level was found in control and lipemic mice pretreated with atorvastatin, fenofibrate, or both. Liver expression of lysosomal acid lipase increased in atorvastatin- or/and fenofibrate-pretreated groups of lipemic mice. It was concluded that increased expression of lysosomal acid lipase is related to the removal of lipid droplets from hepatocytes, thus preventing acute lipemia. Lastly, cystatin C may be a “theranostic” biomarker for hypolipidemic drugs.


  • Therapeutic potential of phytochemicals for cystic fibrosis

    by Hamed Baharara, Prashant Kesharwani, Thomas P. Johnston, AmirHossein Sahebkar

    The aim of this review was to review and discuss various phytochemicals that exhibit beneficial effects on mutated membrane channels, and hence, improve transmembrane conductance. These therapeutic phytochemicals may have the potential to decrease mortality and morbidity of CF patients. Four databases were searched using keywords. Relevant studies were identified, and related articles were separated. Google Scholar, as well as gray literature (i.e., information that is not produced by commercial publishers), were also checked for related articles to locate/identify additional studies. The relevant databases were searched a second time to ensure that recent studies were included. In conclusion, while curcumin, genistein, and resveratrol have demonstrated effectiveness in this regard, it should be emphasized that coumarins, quercetin, and other herbal medicines also have beneficial effects on transporter function, transmembrane conductivity, and overall channel activity. Additional in vitro and in vivo studies should be conducted on mutant CFTR to unequivocally define the mechanism by which phytochemicals alter transmembrane channel function/activity, since the results of the studies evaluated in this review have a high degree of heterogenicity and discrepancy. Finally, continued research be undertaken to clearly define the mechanism(s) of action and the therapeutic effects that therapeutic phytochemicals have on the symptoms observed in CF patients in an effort to reduce mortality and morbidity.


  • Open Access

    The ins and outs of lipoprotein(a) assay methods

    by Maryam Heydari, Majid Rezayi, Massimiliano Ruscica, Tannaz Jamialahmadi, Thomas P. Johnston, Amirhossein Sahebkar

    Pathophysiological, epidemiological and genetic studies convincingly showed lipoprotein(a) (Lp(a)) to be a causal mediator of atherosclerotic cardiovascular disease (ASCVD). This happens through a myriad of mechanisms including activation of innate immune cells, endothelial cells as well as platelets. Although these certainties whether or not Lp(a) is ready for prime-time clinical use remain debated. Thus, remit of the present review is to provide an overview of different methods that have been employed for the measurement of Lp(a). The methods include dynamic light scattering, multi-angle light scattering analysis, near-field imaging, sedimentation, gel filtration, and electron microscopy. The development of multiple Lp(a) detection methods is vital for improved prediction of ASCVD risk.


  • Implications for the role of lipopolysaccharide in the development of atherosclerosis

    by Armita Mahdavi Gorabi, Nasim Kiaie, Arezou Khosrojerdi, Tannaz Jamialahmadi, Khalid Al-Rasadi, Thomas P. Johnston, Amirhossein Sahebkar


  • Statin-regulated phagocytosis and efferocytosis in physiological and pathological conditions

    by Amir Tajbakhsh, Seyed Mohammad Gheibihayat, Hassan Askari, Amir Savardashtaki, Matteo Pirro, Thomas P. Johnston, Amirhossein Sahebkar


  • Immunomodulatory effects of curcumin in systemic autoimmune diseases

    by Sajjad Chamani, Maryam Moossavi, Ali Naghizadeh, Mitra Abbasifard, Muhammed Majeed, Thomas P. Johnston, Amirhossein Sahebkar

    Systemic autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus represent various autoimmune conditions identified by immune system dysregulation. The activation of immune cells, auto‐antigen outbreak, inflammation, and multi‐organ impairment is observed in these disorders. The immune system is an essential complex network of cells and chemical mediators which defends the organism's integrity against foreign microorganisms, and its precise operation and stability are compulsory to avoid a wide range of medical complications. Curcumin is a phenolic ingredient extracted from turmeric and belongs to the Zingiberaceae, or ginger family. Curcumin has multiple functions, such as inhibiting inflammation, oxidative stress, tumor cell proliferation, cell death, and infection. Nevertheless, the immunomodulatory influence of curcumin on immunological reactions/processes remains mostly unknown. In the present narrative review, we sought to provide current information concerning the preclinical and clinical uses of curcumin in systemic autoimmune diseases.


  • Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways

    by Amir R. Afshari, Mehdi Sanati, Hamid Mollazadeh, Prashant Kesharwani, Thomas P. Johnston, Amirhossein Sahebkar


  • The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials

    by Maryam Mohseni, Amirhossein Sahebkar, Gholamreza Askari, Thomas P. Johnston, Babak Alikiaii, Mohammad Bagherniya

    Neuroprotective effects of curcumin have been shown in previous studies. This updated systematic review of clinical trials aimed to investigate the effect of curcumin on neurological disorders. Databases including PubMed, Scopus, Web of Science, and Google Scholar were systematically searched to identify clinical trials investigating the effects of curcumin/turmeric supplements alone, or in combination with other ingredients, on neurological diseases. Nineteen studies comprising 1,130 patients met the inclusion criteria. Generally, intervention and study outcomes were heterogeneous. In most of the studies, curcumin had a favorable effect on oxidative stress and inflammation. However, with the exception of AD, curcumin supplementation either alone, or in combination with other ingredients, had beneficial effects on clinical outcomes for the other aforementioned neurodegenerative diseases. For example, the frequency, severity, and duration of migraine attacks, scores on the revised ALS functional rating scale, and the occurrence of motor complications in PD were all significantly improved with curcumin supplementation either alone or in combination with other ingredients. However, in three studies, several adverse side effects (mostly gastrointestinal in nature) were reported. Curcumin supplementation may have favorable effects on inflammatory status and clinical outcomes of patients with neurological disease, although the results were not consistent.


  • Open Access

    CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways

    by Seyed Mohammad Gheibihayat, Ricardo Cabezas, Nikita G. Nikiforov, Tannaz Jamialahmadi, Thomas P. Johnston, Amirhossein Sahebkar

    CD47 is a receptor belonging to the immunoglobulin (Ig) superfamily and broadly expressed on cell membranes. Through interactions with ligands such as SIRPα, TSP-1, integrins, and SH2-domain bearing protein tyrosine phosphatase substrate-1 (SHPS-1), CD47 regulates numerous functions like cell adhesion, proliferation, apoptosis, migration, homeostasis, and the immune system. In this aspect, previous research has shown that CD47 modulates phagocytosis via macrophages, the transmigration of neutrophils, and the activation of T-cells, dendritic cells, and B-cells. Moreover, several studies have reported the increased expression of the CD47 receptor in a variety of diseases, including acute lymphoblastic leukemia (ALL), chronic myeloid leukemia, non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), bladder cancer, acute myeloid leukemia (AML), Gaucher disease, Multiple Sclerosis and stroke among others. The ubiquitous expression of the CD47 cell receptor on most resident cells of the CNS has previously been established through different methodologies. However, there is little information concerning its precise functions in the development of different neurodegenerative pathologies in the CNS. Consequently, further research pertaining to the specific functions and roles of CD47 and SIRP is required prior to its exploitation as a druggable approach for the targeting of various neurodegenerative diseases that affect the human population. The present review attempts to summarize the role of both CD47 and SIRP and their therapeutic potential in neurodegenerative disorders.


  • Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions

    by Abolfazl Maghrouni, Maryam Givari, Mohammad Jalili-Nik, Hamid Mollazadeh, Bahram Bibak, Mohammad Montazami Sadeghi, Amir R. Afshari, Thomas P. Johnston, Amirhossein Sahebkar